Atossa Genetics Inc. (NASDAQ:ATOS) Files An 8-K Other Events
Item 8.01
| Other Events. |
On December 9, 2016, from 5 p.m. to 7 p.m., a poster was
presented at The San Antonio Breast Cancer Symposium featuring
Atossa Genetic Inc.s (the Company) clinical study titled
OT3-02-08: Open Label, phase 2 safety, efficacy, and
pharmacokinetic study of pre-surgical intramuscular and
intraductal fulvestrant in women with invasive breast cancer or
DCIS undergoing mastectomy or lumpectomy. A copy of the
presentation is attached to this Current Report on Form 8-K as
Exhibit 99.1 and incorporated into this Item 8.01 by this
reference.
This Current Report on Form 8-K contains forward-looking
statements within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of
1934, including statements about the Companys ongoing Phase 2
clinical study. The words may, will, could, would, should,
expect, intend, plan, anticipate, believe, estimate, predict,
project, potential, continue, ongoing and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. While
the Company believes its plans, intentions and expectations
reflected in those forward-looking statements are reasonable,
these plans, intentions or expectations may not be achieved. The
Companys actual results, performance or achievements could differ
materially from those contemplated, expressed or implied by the
forward-looking statements. For information about the factors
that could cause such differences, please refer to the Companys
Annual Report on Form 10-K for the year ended December 31, 2015,
including the information discussed under the captions Item 1
Business, Item 1A. Risk Factors and Item 7 Managements Discussion
and Analysis of Financial Condition and Results of Operations, as
well as the Companys various other filings with the SEC including
reports on Forms 10-Q and 8-K. Given these uncertainties, you
should not place undue reliance on these forward-looking
statements. The Company assumes no obligation to update any
forward-looking statement.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit Number |
Description | |
| 99.1 |
Poster presentation presented December 9, 2016* _________________ *Filed herewith. |
|
(s)
About Atossa Genetics Inc. (NASDAQ:ATOS)
Atossa Genetics Inc. is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ (DCIS) and breast cancer. Its second pharmaceutical program under development is Afimoxifene Topical Gel (AfTG) for the treatment and prevention of hyperplasia of the breast. It is also engaged in the process of evaluating other therapeutic candidates to treat other breast conditions, including breast cancer. Its medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator. These devices are intended for the collection of nipple aspirate fluid (NAF) for cytological testing at a laboratory. Atossa Genetics Inc. (NASDAQ:ATOS) Recent Trading Information
Atossa Genetics Inc. (NASDAQ:ATOS) closed its last trading session down -0.18 at 1.61 with 114,986 shares trading hands.